Bausch Health Announces 2024 Gastrointestinal Health Scholars Program Winners
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology business, Salix Pharmaceuticals, have announced the recipients of the 2024 Salix Gastrointestinal Health Scholars Program. For the fifth consecutive year, 10 students living with GI diseases will each receive a $10,000 scholarship to support their higher education. The awardees were selected from over 275 applications across four categories: Undergraduate Scholar Awards, Graduate Scholar Awards, Single Parent's Scholar Award, and Working Parent's Scholar Award.
The program aims to assist students who balance their academic pursuits with GI challenges. Applicants submitted essays describing their experiences and the role of their healthcare providers in their educational journey. An independent panel of judges reviewed all applications.
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) e la sua divisione di gastroenterologia, Salix Pharmaceuticals, hanno annunciato i destinatari del Programma di Borse di Studio per la Salute Gastrointestinale Salix 2024. Per il quinto anno consecutivo, 10 studenti affetti da malattie intestinali riceveranno ciascuno una borsa di studio di $10.000 per supportare la loro formazione superiore. I premiati sono stati selezionati da oltre 275 candidature suddivise in quattro categorie: Borse di Studio per Studenti Universitari, Borse di Studio per Graduati, Borsa di Studio per Genitori Single e Borsa di Studio per Genitori Lavoratori.
Il programma mira ad assistere gli studenti che bilanciano i loro studi con le sfide legate alla salute intestinale. I candidati hanno presentato saggi descrivendo le loro esperienze e il ruolo dei loro fornitori di assistenza sanitaria nel loro percorso educativo. Un panel indipendente di giudici ha esaminato tutte le candidature.
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) y su negocio de gastroenterología, Salix Pharmaceuticals, han anunciado a los beneficiarios del Programa de Becas para la Salud Gastrointestinal Salix 2024. Por quinto año consecutivo, 10 estudiantes con enfermedades gastrointestinales recibirán cada uno una beca de $10,000 para apoyar su educación superior. Los premiados fueron seleccionados de más de 275 solicitudes en cuatro categorías: Becas para Estudiantes de Pregrado, Becas para Estudiantes de Posgrado, Beca para Padres Solteros y Beca para Padres Trabajadores.
El programa tiene como objetivo ayudar a los estudiantes que equilibran sus estudios académicos con los desafíos gastrointestinales. Los solicitantes enviaron ensayos describiendo sus experiencias y el papel de sus proveedores de atención médica en su trayectoria educativa. Un panel independiente de jueces revisó todas las solicitudes.
바우쉬 헬스 컴퍼니즈 Inc. (NYSE:BHC)(TSX:BHC)와 그들의 위장병학 사업부인 살릭스 제약은 2024년 살릭스 소화 건강 장학 프로그램 수혜자를 발표했습니다. 5년 연속으로, GI 질환을 앓고 있는 10명의 학생들이 각각 $10,000의 장학금을 수여받아 고등 교육을 지원받게 됩니다. 수상자는 275개 이상의 지원서 중에서 학부 장학금, 대학원 장학금, 한부모 장학금, 그리고 맞벌이 부모 장학금의 네 가지 카테고리에서 선정되었습니다.
이 프로그램은 GI 챌린지와 학업을 균형 있게 진행하는 학생들을 지원하는 것을 목표로 합니다. 지원자들은 자신의 경험과 교육적 여정에서 의료 제공자의 역할을 설명하는 에세이를 제출했습니다. 독립적인 심사위원회가 모든 지원서를 검토하였습니다.
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) et son entreprise de gastro-entérologie, Salix Pharmaceuticals, ont annoncé les bénéficiaires du Programme de Bourses d'Études pour la Santé Gastro-Intestinale Salix 2024. Pour la cinquième année consécutive, 10 étudiants vivant avec des maladies gastro-intestinales recevront chacun une bourse de 10 000 $ pour soutenir leur éducation supérieure. Les lauréats ont été sélectionnés parmi plus de 275 candidatures dans quatre catégories : Bourses pour Étudiants de Licence, Bourses pour Étudiants de Master, Bourse pour Parent Isolé et Bourse pour Parent Travaillant.
Le programme vise à aider les étudiants qui équilibrent leurs études avec les défis gastro-intestinaux. Les candidats ont soumis des essais décrivant leurs expériences et le rôle de leurs prestataires de soins de santé dans leur parcours éducatif. Un panel indépendant de juges a examiné toutes les candidatures.
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) und ihr Bereich für Gastroenterologie, Salix Pharmaceuticals, haben die Empfänger des Salix Gastrointestinal Health Scholars Programms 2024 bekannt gegeben. Im fünften Jahr in Folge werden zehn Studierende mit Magen-Darm-Erkrankungen jeweils ein Stipendium von 10.000 $ erhalten, um ihre Hochschulausbildung zu unterstützen. Die Preisträger wurden aus über 275 Bewerbungen in vier Kategorien ausgewählt: Undergraduate Scholar Awards, Graduate Scholar Awards, Stipendium für Alleinerziehende und Stipendium für berufstätige Eltern.
Das Programm zielt darauf ab, Studierenden zu helfen, die ihre akademischen Bestrebungen mit Gastrointestinalerkrankungen in Einklang bringen. Die Bewerber reichten Essays ein, in denen sie ihre Erfahrungen und die Rolle ihrer Gesundheitsdienstleister in ihrem Bildungsweg beschrieben. Ein unabhängiges Gutachtergremium überprüfte alle Bewerbungen.
- Continued commitment to supporting students with GI diseases for the fifth consecutive year
- Awarding $100,000 in total scholarships to 10 students
- None.
For Fifth Consecutive Year, 10 Students with Gastrointestinal Disease Will Each Receive a
LAVAL, QC / ACCESSWIRE / August 13, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2024 Salix Gastrointestinal Health Scholars Program. For the fifth year, Bausch Health is proud to award 10 deserving students living with a GI disease
"Bausch Health is proud of the number of applications we received in our fifth year of the program - a true testament to the unrelenting strength of the GI community," said Aimee Lenar, Executive Vice President, US Pharma, Bausch Health. "We know it can be difficult to juggle higher education with GI challenges, so we remain dedicated to providing financial assistance to students who have not allowed their disease to stand in the way of their academic achievements."
The 2024 awardees were selected from more than 275 applications. As part of the process, applicants were required to submit essays describing how their GI condition has impacted their educational journey, as well as explore the role their health care provider(s) played in helping them reach both their personal and educational goals. All scholarship applications were reviewed by an independent panel of judges.
The program recognizes students across a wide range of educational pursuits, with scholarships in four categories, including the Undergraduate Scholar Awards, for those pursuing undergraduate degrees; the Graduate Scholar Awards, for those pursuing graduate degrees; the Single Parent's Scholar Award, for students who are single parents; and the Working Parent's Scholar Award, for parents pursuing undergraduate, vocational/technical, or graduate degrees.
"Receiving this scholarship has been a tremendous honor. I feel proud to live in a world where I am able to achieve great things even with this condition," said Milo Eaton, a scholarship recipient. "I'd like to thank Bausch Health for helping me pursue my dreams."
The 2024 Salix Gastrointestinal Health Scholars Program recipients are:
Undergraduate Scholar Awards
Abigail Singer - University of Michigan
Milo Eaton - Emerson College
Divya Mehrish - Stanford University
Sophia Zar - University of Pittsburgh
Graduate Scholar Awards
Rohit Aita - University of Pittsburgh
Kendall Ciesemier - Harvard Divinity School
Aisha Young - Emory University
Kyle Weil - Harvard Business School
Single Parent's Scholar Award
Kourtney Moon - Austin Community College
Working Parent's Scholar Award
Jasmine Castigliano - Antioch University Seattle
To learn more about the Salix Gastrointestinal Health Scholars Program, visit www.salix.com/scholarship or visit www.bauschhealth.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals and eye health through our approximately
About Salix
Salix Pharmaceuticals is one of the largest specialty pharmaceutical businesses in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn.
###
Investor Contact: |
| Media Contact: |
Garen Sarafian |
| Katie Savastano |
| ||
877-281-6642 (toll-free) |
| 908-569-3692 |
SOURCE: Bausch Health Companies Inc.
View the original press release on accesswire.com
FAQ
What is the Salix Gastrointestinal Health Scholars Program by Bausch Health (BHC)?
How many scholarships were awarded by Bausch Health (BHC) in the 2024 Gastrointestinal Health Scholars Program?
What are the categories for the Bausch Health (BHC) Gastrointestinal Health Scholars Program?
How many applications did Bausch Health (BHC) receive for the 2024 Gastrointestinal Health Scholars Program?
